Venrock

SmithRx and Mark Cuban Cost Plus Drug Company Announce $9.5 Million in Client Savings Through Innovative Autoimmune Drug Sourcing

Retrieved on: 
Monday, March 4, 2024

SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.

Key Points: 
  • SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.
  • This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs.
  • This successful alliance combines SmithRx's patient-first approach with Cost Plus Drugs’ revolutionary drug pricing strategy to tackle the highest cost drug category for many employers.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.

Beyond ETFs: Integral secures investment from Franklin Templeton to build tokenization accounting infrastructure

Retrieved on: 
Wednesday, February 28, 2024

The goal for the investment and collaboration is to advance digital asset accounting tooling for new technologies, including tokenization.

Key Points: 
  • The goal for the investment and collaboration is to advance digital asset accounting tooling for new technologies, including tokenization.
  • "At Integral, we built a core ledgering solution that makes it easy for finance and accounting teams to bring new products to market, without accounting and compliance headaches.
  • What's special about Integral is that our infrastructure allows us to move as fast as crypto.
  • We are excited to work with Franklin Templeton to develop accounting and financial operations software that institutions with digital assets can rely on and innovate with," said Laliberté.

Molly He Honored as a CNBC Changemaker in Inaugural List of Women Transforming Business

Retrieved on: 
Wednesday, February 28, 2024

As a first-generation Asian female leader, Molly was honored by CNBC for spearheading a remarkable undertaking to democratize sequencing and biological tools globally.

Key Points: 
  • As a first-generation Asian female leader, Molly was honored by CNBC for spearheading a remarkable undertaking to democratize sequencing and biological tools globally.
  • Her work is a reflection of her commitment to collaborative science through fairness and accessibility for the research community.
  • "Today is a great honor and a true testament to the journey the Element team has embarked on together since the company's founding," Molly He said.
  • "We are incredibly proud to see Molly recognized on CNBC's inaugural Changemakers list," said Bryan Roberts, PhD, partner at Venrock and member of the Element Biosciences Board of Directors.

Family Offices Investors Summit to Spotlight 'Beyond Wealth: A Legacy of Leadership for the Younger Generation' at the World Economic Forum 2025

Retrieved on: 
Wednesday, February 7, 2024

New York, New York--(Newsfile Corp. - February 7, 2024) - Anticipating a transformative gathering, The Family Offices Investors Summit announces its 2025 edition during the World Economic Forum Annual Meeting in Davos.

Key Points: 
  • New York, New York--(Newsfile Corp. - February 7, 2024) - Anticipating a transformative gathering, The Family Offices Investors Summit announces its 2025 edition during the World Economic Forum Annual Meeting in Davos.
  • In the spirit of looking ahead, the summit will spotlight insights from thought leaders like Dr. Bill Tai, Eduardo Esparza, Carolina Forga, Mamadou Kwidjim Toure, and Manana Samuseva.
  • The Summit is a call to action, advocating for investments that align financial success with social impact and responsibility.
  • Family Offices & Investors Summit is an elite conference for Family Offices, Funds of Funds, Private Equity, Hedge Funds, and Venture Capitalists managing assets over $100M.

SmithRx Continues to Fix Broken Pharmacy Benefits Management System, Closes $60M in Series C Funding Led by Venrock

Retrieved on: 
Tuesday, January 23, 2024

SmithRx , a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022.

Key Points: 
  • SmithRx , a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022.
  • Led by top Silicon Valley healthcare venture capital firm Venrock , the latest funding positions SmithRx to continue reducing costs of pharmacy benefits for small and midsize self-insured businesses.
  • “Medications in the U.S. cost too much because the overall system is broken,” said Jake Frenz , founder and CEO of SmithRx.
  • “At the core of this broken system are pharmacy benefit managers that drive up the costs.

MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates

Retrieved on: 
Tuesday, November 14, 2023

Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.

Key Points: 
  • Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.
  • The round also included new investors Avidity Partners and Cowen Healthcare Investments, as well as existing Series A investors, Venrock and Alta Partners.
  • MBrace has generated extensive preclinical data on novel drug candidates in-licensed from Rutgers, The State University of New Jersey.
  • XinThera is a subsidiary of Gilead Pharmaceuticals that is focused on small molecule discovery and development of oncology and immunology therapeutics.

Achieving Five-Fold Revenue Growth, Zero Networks Raises $20M in Series B to Prevent Attackers from Spreading in Corporate Networks

Retrieved on: 
Wednesday, December 13, 2023

ORLANDO, Fla. and TEL AVIV, Israel, Dec. 13, 2023 /PRNewswire/ -- Israeli cybersecurity startup Zero Networks, a leading provider of zero trust identity and network security solutions, raised $20 million in Series B funding following a five-fold increase in its revenue, bringing its total raised capital to $45 million.

Key Points: 
  • The funds will be utilized to recruit development, marketing, and sales personnel, supporting Zero Networks' hypergrowth.
  • Zero Networks was founded in 2019, and is led by Benny Lakunishok, the CEO, and Amir Frankel, the CTO.
  • In addition, Zero Networks enables organizations to securely connect remote employees and third parties to their network with zero trust principles and maximum network performance.
  • Now, I'm excited to help Zero Networks revolutionize the other huge market that is ripe for disruption - Network Security."

Achieving Five-Fold Revenue Growth, Zero Networks Raises $20M in Series B to Prevent Attackers from Spreading in Corporate Networks

Retrieved on: 
Wednesday, December 13, 2023

ORLANDO, Fla. and TEL AVIV, Israel, Dec. 13, 2023 /PRNewswire/ -- Israeli cybersecurity startup Zero Networks, a leading provider of zero trust identity and network security solutions, raised $20 million in Series B funding following a five-fold increase in its revenue, bringing its total raised capital to $45 million.

Key Points: 
  • The funds will be utilized to recruit development, marketing, and sales personnel, supporting Zero Networks' hypergrowth.
  • Zero Networks was founded in 2019, and is led by Benny Lakunishok, the CEO, and Amir Frankel, the CTO.
  • In addition, Zero Networks enables organizations to securely connect remote employees and third parties to their network with zero trust principles and maximum network performance.
  • Now, I'm excited to help Zero Networks revolutionize the other huge market that is ripe for disruption - Network Security."

Distinguished Trio Joins SHINE Technologies' Board to Drive Growth

Retrieved on: 
Thursday, December 7, 2023

JANESVILLE, Wis., Dec. 7, 2023 /PRNewswire/ -- SHINE Technologies, a global leader in nuclear fusion technology and radioisotope production, is proud to announce the appointment of three highly accomplished individuals to its Board of Directors: Ray Rothrock, Sue Marks, and Gordon Gunnlaugsson.

Key Points: 
  • SHINE announces the appointment of three distinguished board members, Ray Rothrock, Sue Marks, and Gordon Gunnlaugsson.
  • Ray Rothrock is a seasoned venture capitalist, tech investor, and cyber security expert with a distinguished track record in early-stage technology investments.
  • His extensive background in nuclear engineering, coupled with his business acumen, makes him a valuable addition to SHINE's board.
  • These three distinguished board members join SHINE at an exciting time as the company expands its global presence and reinforces its commitment to nuclear fusion technology and radioisotope production.

Amplica Labs Welcomes Mickey Maher as Chief Business Officer

Retrieved on: 
Friday, November 10, 2023

LOS ANGELES, Nov. 10, 2023 /PRNewswire/ -- Amplica Labs (formerly Unfinished Labs), a company developing critical infrastructure for the builders of the next era of social networking apps, today announced the appointment of Mickey Maher as its first Chief Business Officer (CBO). In this pivotal new role, Maher will work alongside Amplica Labs' senior leadership team to target partnership opportunities, lead collaboration with corporate and non-profit partners, and spearhead strategic planning efforts around growth opportunities.

Key Points: 
  • LOS ANGELES, Nov. 10, 2023 /PRNewswire/ -- Amplica Labs (formerly Unfinished Labs), a company developing critical infrastructure for the builders of the next era of social networking apps, today announced the appointment of Mickey Maher as its first Chief Business Officer (CBO).
  • Maher has an extensive background in business development and blockchain technology and recently worked as the Senior Vice President of Platform and Blockchain Partnerships at Dapper Labs.
  • "We're incredibly excited to have Mickey join our team," said Braxton Woodham, President of Amplica Labs.
  • "I'm thrilled to have this opportunity to continue my work bringing the benefits of Web3 technology to the masses with the talented team at Amplica Labs," said Maher.